Skeletal muscle cell MHC I expression: Implications for statin-induced myopathy

Muscle and Nerve

Volumn 41, Issue 2, 2010, Pages 179-184

  Singh, Pratibha ^a   Kohr, Danielle ^a   Kaps, Manfred ^a   Blaes, Franz ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

LMP; MHC class I; Myopathies; Statins; TAP

Indexed keywords

COMPACTIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVINOLIN; SIMVASTATIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CONTROLLED STUDY; DRUG INDUCED DISEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MUSCLE CELL; MYOPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RHABDOMYOSARCOMA; SKELETAL MUSCLE;

CELL LINE, TUMOR; CELLS, CULTURED; GENE EXPRESSION REGULATION; GENES, MHC CLASS I; HLA ANTIGENS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON-GAMMA; MUSCLE NEOPLASMS; MUSCLE, SKELETAL; MUSCULAR DISEASES; RHABDOMYOSARCOMA;

EID: 76649134804     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21479     Document Type: Article

References (26)

1. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-370.
2. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007;17:194-200.
3. Nagaraju K. Role of major histocompatibility complex class I molecules in autoimmune myositis. Curr Opin Rheumatol 2005;17:725-730.
4. Hohlfeld R, Engel AG. HLA expression in myoblasts. Neurology 1991;41:2015.
5. Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998;113:407-414.
6. Appleyard ST, Dunn MJ, Dubowitz V, Rose ML. Increased expression of HLA ABC class I antigens by muscle fibers in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders. Lancet 1985;1:361-363.
7. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989;20:224-231.
8. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000;97:9209-9214.
9. Raghavan M, Del Cid N, Rizvi SM, Peters LR. MHC class I assembly: out and about. Trends Immunol 2008;29:436-443.
10. Elliott T. Transporter associated with antigen processing. Adv Immunol 1997;65:47-109.
11. Driscoll J, Brown MG, Finley D, Monaco JJ. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 1993;365:262-264.
12. Gaczynska M, Rock KL, Spies T, Goldberg AL. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc Natl Acad Sci USA 1994;91:9213-9217.
13. Groettrup M, Ruppert T, Kuehn L, Seeger M, Standera S, Koszinowski U, et al. The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J Biol Chem 1995;270:23808-23815.
14. Niedermann G, Butz S, Ihlenfeldt HG, Grimm R, Lucchiari M, Hoschutzky H, et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 1995;2:289-299.
15. Boes B, Hengel H, Ruppert T, Multhaup G, Koszinowski UH, Kloetzel PM. Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med 1994;179:901-909.
16. Tanaka K. Role of proteasomes modified by interferon-gamma in antigen processing. J Leukoc Biol 1994;56:571-575.
17. Yang Y, Waters JB, Fruh K, Peterson PA. Proteasomes are regulated by interferon gamma: implications for antigen processing. Proc Natl Acad Sci USA 1992;89:4928-4932.
18. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45
19. Sundaram C, Uppin MS, Meena AK. Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. Neurol India 2008;56:363-367.
20. Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today 1994;15:269-274.
21. Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, Mariani E, et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 2003;142:130-136.
22. Tilkin-Mariame AF, Cormary C, Ferro N, Sarrabayrouse G, Lajoie-Mazenc I, Faye JC, et al. Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression. FASEB J 2005;19:1513-1515.
23. Kostek CA, Dominov JA, Miller JB. Up-regulation of MHC class I expression accompanies but is not required for spontaneous myopathy in dysferlin-deficient SJL/J mice. Am J Pathol 2002;160:833-839.
24. Chinoy H, Salway F, John S, Fertig N, Tait BD, Oddis CV, et al. Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. Ann Rheum Dis 2007;66:970-973.
25. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008;359:789-799.
26. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82:726-733.